Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Enrolment into the hydroxychloroquine group of a trial evaluating a range of possible treatments in patients hospitalised with Covid-19 was closed early due to lack of efficacy noted in an interim analysis, with no reduction in death within 28 days (27% v 25% usual care; P=0.15).

New England Journal of Medicine